Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CompumedicsASX:CMP +2.27%55 3-Year FCF Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates ASX:CMP with a GF Score™ of 55/100 and a GF Value™ of A$0.32 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 585 Medical Devices & Instruments companies, Compumedics ranks worse than 170940% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Compumedics was 50.00% per year. The lowest was -157.10% per year. And the median was 3.15% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Compumedics 3-Year FCF Growth Rate Related Terms
ASX:CMP vs ABT, SYK, MDT: 3-Year FCF Growth Rate Comparison
For the Medical Devices subindustry, Compumedics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Compumedics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Compumedics (ASX:CMP) has a 3-Year FCF Growth Rate of 0.00% as of Dec. 2025. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Compumedics and its competitors. According to the industry distribution chart, Compumedics ranks #999999 out of 585 companies in the Medical Devices & Instruments industry.
Is Compumedics' 3-Year FCF Growth Rate too high?
Compumedics' current 3-Year FCF Growth Rate is 0.00%. Based on the distribution chart, Compumedics ranks #999999 out of 585 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Compumedics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compumedics' 3-Year FCF Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #999999 out of 585 companies for 3-Year FCF Growth Rate. This places Compumedics in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 17.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 17.90, based on 585 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Compumedics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 17.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current 3-Year FCF Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.32, compared to a current price of A$0.23 — trading 29.7% below its estimated fair value. The current 3-Year FCF Growth Rate is 0.00%. Compumedics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current 3-Year FCF Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.23 is trading 29.7% below its estimated GF Value™ of A$0.32.
GuruFocus considers Compumedics to be Possible Value Trap.
Key valuation signals for ASX:CMP:
3-Year FCF Growth Rate: 0.00%
GF Value™: A$0.32 vs. price of A$0.23 (29.7% below fair value)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
55GF Score
Get the complete analysis for ASX:CMP
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
